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Objectives: Our objective was to identify surgical–pathologic factors affecting prognosis in stage IB non–small
cell lung cancers.
Methods: Between 1997 and 2006, a cohort of 272 cases of pT2 N0 M0 stage lung cancer were retrospectively
analyzed. The patients included 70 women and 202 men with a mean age of 67.0 years. The surgical resections
included pneumonectomy in 4, bilobectomy or lobectomy in 217, and limited resections in another 51. The im-
pact of surgical–pathologic characteristics on survival, including cell type, tumor differentiation, tumor size,
depth of visceral pleural invasion, type of surgical resection, and extent of lymphadenectomy on patient survival,
was compared accordingly.
Results: Tumor types included adenocarcinoma/bronchioloalveolar carcinoma in 142, squamous cell carcinoma
in 100, and others in 30. Cell differentiations were classified as well, moderately, and poorly differentiated in 23,
151, and 92 cases, respectively. The mean tumor size was 3.9 cm in diameter, and the average resected lymph
node number was 14.3. Direct visceral pleural or subpleural invasions (<1 mm) were found in 134 and 42 cases,
respectively. Angiolymphatic invasions were seen in 26 cases, and positive tumor margins were found in 14
cases. The overall 5-year and 10-year survivals were 59.5% and 41.3%, respectively. Good prognostic factors
using univariate analysis included female gender, nonlimited resection, well-differentiated tumor, no angiolym-
phatic invasion, smaller size (3 cm), and numbers of nodes retrieved (>14 nodes). However, the Cox propor-
tional hazard model revealed female gender, well-differentiated tumor, no pleural involvement, no
angiolymphatic invasion, and more than 14 nodes retrieved as independent good prognostic factors.
Conclusions: Stage IB lung cancer can be treated by standard pulmonary resection accompanied by adequate
mediastinal lymphadenectomy. Owing to the heterogeneity of stage IB lung cancer and the fact that prognosis
can be affected by many surgical–pathologic factors, refinement of the current TNM staging criteria may be
needed.The T2 descriptors in International Union Against Cancer/
American Joint Committee on Cancer (UICC/AJCC) stag-
ing for NSCLCs comprise a heterogeneous group of tumors.
Differences in survival of patients with stage IB (pT2 N0
M0) cancer may be caused by individualized pathologic
characteristics or may be due to different T2 categories
used for staging. The reported incidence of stage IB tumors
was between 10% and 21%.1,2 Surgery remains the treat-
ment of choice for localized diseases like stage IB tumors,
and the 5-year survival is between 57% and 66%.1,2 Em-
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doi:10.1016/j.jtcvs.2008.12.035426 The Journal of Thoracic and Cardiovascular Surphasis is on tumor size as the key denominator in prediction
of outcomes of stage IB tumors.3 The role of mediastinal
lymphadenectomy in the staging and treatment of NSCLC
remains controversial. Mediastinal nodal sampling is the
standard in most surgical practices in North America; how-
ever, the importance of routine radical mediastinal lymph
node dissection has been repeatedly raised, especially by
Japanese surgeons.2,4,5 A complete mediastinal lymphade-
nectomy is critical for accurate tumor staging, but its thera-
peutic effect is still a subject of debate.
The currently used TNM staging system for NSCLC was
proposed in 1997 and has never been revised.2 In the past
decade, there has been renewed interest among chest physi-
cians in the prognostic significance of tumor size in early-
stage NSCLC. This is mainly due to the improved ability
of the latest computed tomographic (CT) scanners in detect-
ing small tumors.6 Furthermore, a better understanding of
the tumor’s biological behavior has led to proposals for us-
ing tumor biomarkers as prognostic predictors.7 In stage IB
status, patients with larger tumors (>5 cm) may need adju-
vant chemotherapy owing to poorer prognosis.8 All of these
findings suggest that a revision of the current staginggery c August 2009
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AJCC ¼ American Joint Committee on Cancer
BAC ¼ bronchioalveolar carcinoma
CT ¼ computed tomography
P0 ¼ no visceral pleural invasion
P1 ¼ contiguous subpleural invasion
P2 ¼ direct visceral pleural invasion
UICC ¼ International Union Against Cancer
VPI ¼ visceral pleural invasion (involvement)
category concerning stage IB tumors may be required. How-
ever, even the latest TNM revision for lung cancer staging
proposed by the International Association for the Study of
Lung Cancer ignores surgical–pathologic characteristics.9
The aim of this study was to identify surgical–pathologic
factors that affect prognosis of stage IB NSCLC based on
10 years of experience in a single institute.
PATIENTS AND METHODS
Follow-up
Between 1997 and 2006, the cases of 960 patients with primary NSCLC
who underwent surgical resection in this institute were retrospectively re-
viewed. In this patient cohort, 323 patients with pathologic T2 N0 M0 stage
among a total of 586 pT2 tumors were found. After exclusion of patients (1)
who had received preoperative or postoperative chemotherapy (25 patients),
(2) who had inadequate lymphadenectomy (total number of removed lymph
nodes<6) (18 patients), and (3) who had a history of additional malignancy
(8 patients), a cohort of 272 patients were included in this study. The pa-
tients included 70 women and 202 men with a mean age of 67.0 years
(19–87 years). During the same study period, 57 consecutive patients
with pathologic T1 N0 M0 (stage IA) were also included for survival com-
parison. This study project was approved by the Institutional Review Board
of Taichung Veterans General Hospital (No. C08126). There was no subject
intervention and no identifying link to subjects.
Typically, lobectomies or pneumonectomies with systemic lymphade-
nectomy were performed according to institutional policy. Wedge resec-
tions or segmentectomies were performed in patients with peripheral
lesions or in patients with poor performance scores or significantly impaired
pulmonary function. For patients who underwent sublobar resection, lymph
node sampling was performed. All pulmonary resections were performed by
thoracotomy, and surgical resections included pneumonectomy in 4, bilo-
bectomy or lobectomy in 217, and limited resections in another 51. All of
the resected lymph nodes were labeled separately. The impact of pathologic
characteristics on patient survival including, cell type, cell differentiation,
tumor size, depth of visceral pleural invasion (VPI), type of surgical resec-
tion, and extent of lymphadenectomy, was compared accordingly. P2 indi-
cates direct VPI, P1 indicates contiguous subpleural invasion (1 mm), and
P0 indicates no VPI. Patients with a positive resection margin were boosted
with local adjuvant radiotherapy (5000–5400 rads).
Preoperative thoracic CT scan, whole body bone scanning, and liver so-
nography were performed on all patients to establish tumor staging and to
rule out systemic metastasis. A positron emission tomographic scan was
performed when mediastinal lymphadenopathy was found by CT scan. Me-
diastinoscopy was performed when both CT and positron emission tomo-
graphic scan showed positive mediastinal lymphadenopathy. Tumor
staging and mediastinal lymph node grouping were performed according
to the UICC (fifth edition) criteria.10 Surgical–pathologic characteristics
including cell type, tumor differentiation, tumor size, degree of pleuralThe Journal of Thoracic and Cinvasion, type of surgical resection, and extent of lymphadenectomy were
recorded accordingly for evaluation of their impact on patient survival.
The demographic data of the patients are listed in Table 1.
After discharge from the hospital, all patients were followed up at 2- to 3-
month intervals until death or the end of the study period. The follow-up
protocol included physical examination of patients, chest radiography, tu-
mor markers, whole body bone scanning, liver sonography, and CT scan-
ning of the chest every 3 to 4 months for the first 2 years and every 6
months thereafter until the fifth postoperative year.
Statistical Analysis
Cumulative survival curves were calculated and drawn by the Kaplan–
Meier method and subgroups were compared by the log–rank statistic. Mul-
tivariate analyses were performed with the Cox proportional hazards model.
All probabilities were 2-tailed. The statistical calculations were conducted
with SPSS software (V11.0, SPSS, Inc, Chicago, Ill).
RESULTS
Current Patient Status
At the end follow-up date of this study (December 31,
2007), 164 patients were alive (including 12 patients with
disease recurrence), and 108 patients were dead. Among
the deceased patients, 5 (1.8%) died of postoperative com-
plications, 19 died of other nonmalignant causes, and 84 pa-
tients died of tumor recurrence (local in 27, systemic in 35,
both in 22). None of our patients were lost to follow-up dur-
ing the study period. The follow-up period ranged from 12 to
129 months (mean/median, 84.1/103.6 months). To reflect
the overall survival status, we did not exclude hospital mor-
talities and noncancer-related deaths from the survival anal-
ysis. The overall length of survival is shown in Figure 1.
Types of Resection
All pulmonary resections were performed by thoracot-
omy, and surgical resections include pneumonectomy in 4,
bilobectomy or lobectomy in 217, wedge resection in 41,
and segmentectomy in 10. The cumulative 5-year survivals
for pneumonectomy, bilobectomy or lobectomy, wedge re-
section, and segmentectomy were 75.0%, 62.9%, 44.0%,
and 40.0%, respectively, and the cumulative 10-year sur-
vivals for pneumonectomy, bilobectomy or lobectomy,
wedge resection, and segmentectomy were 75.0%,
42.9%, 30.2%, and 20.0%, respectively (Figure 2, A; P ¼
.0182). Bilobectomy or lobectomy had a better prognosis
when compared with limited resection (Figure 2, B, P ¼
.0051).
Cell Types and Tumor Differentiation
Pathologic types included adenocarcinoma in 142, squa-
mous cell carcinoma in 100, and other types in 30. Tumors
were well differentiated in 23, moderately differentiated in
151, poorly differentiated in 92, and unknown in 6. The cu-
mulative 5-year survivals for squamous cell carcinomas, ad-
enocarcinomas, and other cell types were 56.6%, 57.9%,
and 75.4%, respectively, and the cumulative 10-year sur-
vivals were 38.0%, 40.7%, and 75.4%, respectivelyardiovascular Surgery c Volume 138, Number 2 427
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were pure bronchioalveolar carcinoma (BAC), and 23 had
a focal BAC pattern. The cumulative 5-year survivals for
pure adenocarcinoma, adenocarcinoma with focal BAC,
and pure BAC were 54.3%, 67.6%, and 74.2%, respec-
tively, and the cumulative 10-year survivals in pure adeno-
carcinoma, adenocarcinoma with focal BAC, and pure
BAC were 35.8%, 67.6%, and 49.4%, respectively (P ¼
.2056). Pure BAC and BAC-containing adenocarcinoma
showed a trend toward better prognosis when compared
with pure adenocarcinoma (Figure 3,B; P¼.0763). In regard
to tumor differentiation, well-differentiated tumors had the
best survival (84.4% at 5 years and 67.5% at 10 years) as
compared with their counterparts (Figure 4; P ¼ .0008).
TABLE 1. Demographic data on 272 patients with pT2 N0 M0 stage IB
NSCLC
Variables No. of patients
Gender
Male 202
Female 70
Age (y) 67.0 (19–87)
Tumor location
Right upper lobe 83
Right middle lobe 23
Right lower lobe 42
Left upper lobe 81
Left lower lobe 43
Types of resection
Pneumonectomy 4
Bilobectomy or lobectomy) 217
Segmentectomy 10
Wedge resection 41
Extent of lymphadenectomy
D1 (without mediastinal lymphadenectomy) 36
D2 (with mediastinal lymphadenectomy) 236
Cell types
Adenocarcinoma 142
Squamous cell carcinoma 100
Others 30
Tumor differentiation
Well differentiated 23
Moderately differentiated 151
Poorly differentiated 92
Unknown 6
Angiolymphatic invasion
Yes 26
No 246
Cut margin involvement
Yes 14
No 258
Pleural involvement
P0 (no involvement) 96
P1 (contiguous subpleural involvement) 42
P2 (direct pleural involvement) 134
NSCLC, Non–small cell lung cancer.428 The Journal of Thoracic and Cardiovascular SuTumor Size
The tumor size ranged between 1 and 13 cm in diameter
(mean 3.9 cm). Thirty-six (13.2%) tumors were 2 cm or
less in diameter, and 107 (39.3%) tumors were 3 cm or less
in across. Patients with tumors 2 cm or less in diameter had
a better prognosis than their counterparts (P¼ .0493); patients
with tumors 3 cm or less in diameter also had better prognosis
than their counterparts (Figure 5; P¼ .0159). Subgroup anal-
ysis of patients with tumors 3 cm or less in diameter who also
had pleural involvement (P2) did not demonstrate survival
differences when compared with their counterparts (P ¼
.1327). Similar findings were observed when the cutoff size
was changed to 2 cm or less in diameter (P ¼ .2126).
Visceral Pleural Involvement (VPI)
Direct visceral pleural (P2), subpleural invasion (P1), and
no pleural invasion were found, respectively, in 134, 42,
and 96 cases. The cumulative 5-year survivals for the P0,
P1, and P2 groups were 64.3%, 58.7%, and 56.1%, respec-
tively, and the cumulative 10-year survivals in the P0, P1,
and P2 groups were 41.1%, 50.3%, and 36.6%, respectively
(Figure 6, A; P ¼ .3393). Intergroup comparisons (P0 vs P1,
P1 vs P2, P0 vs P2, P0 vs P1þP2, P0þP1 vs P2) did not show
significant differences in survivals. Tumors without pleural
involvement (P0) were smaller than their counterparts (3.71
 1.22 cm vs 4.06 2.03 cm; P¼ .073). Subgroup analysis
of patients with P2 lesions who also had tumors 3 cm or less in
diameter did not demonstrate survival differences when com-
pared with their counterparts (P ¼ .1694). Similar findings
were observed when the cutoff size was changed to 2 cm or
less in diameter (P ¼ .2705). However, when P2 and P1 le-
sions were combined, tumors of 3 cm or less (2.52  0.56
cm) demonstrated better survivals than did their counterparts
(5.16  1.98 cm) (Figure 6, B; P ¼ .0153).
FIGURE 1. Overall survival times of 57 patients with pT1 N0 M0 (stage
IA) and 272 patients with pT2 N0 M0 (stage IB) non–small cell lung cancer
after resection.rgery c August 2009
Hsu et al General Thoracic SurgeryFIGURE 2. Survival analysis according to the types of resection. A, Survival curves for P (pneumonectomy), L (lobectomy), Bi-L (bilobectomy or lobec-
tomy), W (wedge resection), and S (segmentectomy). B, Survival curves according to standard resections and limited resections.G
T
SExtent of Nodal Dissection
The total number of retrieved nodes was between 6 and 58
(mean 14.3). The average numbers of retrieved nodes in N1
and N2 stations were 5.4 and 8.9, respectively. Patients
with more than 14 retrieved nodes had 5-year and 10-year
survivals of 71.1% and 53.8%, respectively (Figure 7, A;
P ¼ .0049). The majority of patients (86.8%) had received
at least one mediastinal nodal station lymphadenectomy (D2
dissection in 236; 1 to 5 stations, mean, 2.2 stations). Pa-
tients who received D2 dissection had better outcomesThe Journal of Thoracic and Cthan did patients who received D1 dissection (without medi-
astinal lymphadenectomy) (Figure 7, B; P ¼ .0019).
Angiolymphatic Invasion and Resection Margin
Angiolymphatic invasions were identified in 26 (9.6%)
tumors, and patients with these tumors had a poorer progno-
sis (29.6% at 5 years and 29.6% at 10 years) than did their
counterparts (62.7% at 5 years and 43.1% at 10 years;
Figure 8; P¼ .0068). Positive resection margins were found
in 14 (5.1%) patients, including 9 at the bronchial cut endFIGURE 3. Survival analysis according to tumor types. A, Survival curves for squamous cell carcinomas, adenocarcinomas, and other cell types. B, Survival
curves according to the presence of BAC (bronchioloalveolar carcinoma) patterns. AdenocarcinomaþBAC, Adenocarcinoma with focal BAC component;
BAC, pure bronchioloalveolar carcinoma.ardiovascular Surgery c Volume 138, Number 2 429
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were found between the two groups (P ¼ .3548).
Cox Proportional Hazards Survival Analyses
Important prognostic factors such as gender, operation
type, pathologic cell type, tumor differentiation, tumor
size, pleural involvement, angiolymphatic invasion, and ex-
tent of lymphadenectomy were incorporated into the Cox
proportional hazards model. Independent prognostic indica-
tors included gender (P¼ .0008), tumor differentiation (P¼
.0024), pleural involvement (P¼ .0130), angiolymphatic in-
vasion (P ¼ .0500), and number of lymph nodes retrieved
(P ¼ .0118). The hazard ratio and 95% confidence interval
for individual parameters are listed in Table 2.
DISCUSSION
Although sublobar resection is thought to be associated
with increased incidence of local recurrence when compared
with lobectomy, El-Sherif and associates11 found no differ-
ence in disease-free survival between the two types of resec-
tion in patients with stage IA disease, but slightly worse
disease-free survival for those with stage IB. Kraev and
colleagues12 reported patients with tumors less than 3 cm
in size had improved survival times after lobectomy. In
the current study, only 4 (1.5%) patients required pneumo-
nectomy owing to central location or proximity to vessels.
The majority of patients had lobectomy or bilobectomy
(79.8%). When compared with sublobar resection, survival
benefits were observed (62.9% vs 42.9% at 5 years; P ¼
.0051). Lobectomy is a time-honored procedure for stage
IB tumors.
Tumor size plays a critical role in determination of prog-
nosis, especially in early-stage lung cancers without nodal
metastasis. Data from the Surveillance, Epidemiology, and
End Results registry demonstrated that when tumors were
FIGURE 4. Survival analysis according to cell differentiation. Well-differ-
entiated (W) tumors had 5-year and 10-year survivals of 84.4% and 67.5%,
respectively. M, Moderately differentiated; P, poorly differentiated.430 The Journal of Thoracic and Cardiovascular Susmall (<2 cm), lung cancer–associated mortality was similar
for adenocarcinoma and squamous cell carcinoma. In tu-
mors 3 cm or larger in size, lung cancer–associated mortality
was higher for adenocarcinoma.13 Mizuno and coworkers14
reported that stage IB cases with BAC-dominant histologic
characteristics had lower rates of lymphatic permeation, vas-
cular invasion, and pleural invasion. The distribution of ad-
enocarcinomas and squamous cell carcinomas was similar in
our series; moreover, long-term survivals of the two groups
were similar, too (Figure 3, A). We15 previously reported
a better surgical outcome in patients with localized (nodular)
type BAC tumors compared with diffuse (infiltrative) type.
Pure BAC and focal BAC patterns were found in 22.5%
(32/142) of the adenocarcinomas in the current study. Sub-
group comparison survival between pure adenocarcinomas
and BAC-containing adenocarcinomas showed a trend to-
ward better outcomes in the latter group (Figure 3, B). In
regard to tumor differentiation, moderately and poorly
differentiated tumors comprised more than 90% of the
whole series. Although less frequently encountered, well-
differentiated tumors showed the best survival (84.4% at 5
years and 67.5% at 10 years), which is almost the same as
that for stage IA tumors (Figure 4).
Asamura and coworkers,16 using the Japanese Lung Can-
cer Registry data, suggested T1 tumors could be divided into
T1a (2.0 cm at the greatest diameter) and T1b (2.1–3.0 cm
at the greatest diameter) subcategories according to size. In
the proposed staging system, the authors defined T1a N0
M0 as new stage IA and T1b N0 M0 as new stage IB. T2
N0 M0 (stage IB) and T1 N1 M0 (stage IIA) were combined
and defined as new stage IIA.16 Our data indicated that pa-
tients with tumors 3 cm or less in diameter survived better
than their counterparts. If we change the cutoff diameter to
2 cm, the survival difference between the two groups persists
(P ¼ .0493).
FIGURE 5. Survival analysis according to tumor size. Patients with tu-
mors less than 2 cm and 3 cm in diameter both had better long-term survivals
than did their counterparts.rgery c August 2009
Hsu et al General Thoracic SurgeryFIGURE 6. A, Survival analysis according to the depth of visceral invasion in all groups. B, After exclusion of P0 group, patients with tumors of 3 cm or less
in diameter had better long-term survivals than did their counterparts.G
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cant of VPI and the number of patients with stage IB NSCLC
in whom staging is done solely according to VPI. In tumors
less than 3 cm in diameter, the distinction between stages IA
and IB depends on existence of VPI. Disruption of elastic
lamina, the key histologic landmark, is essential for diagno-
sis of VPI.17 Taube and coworkers18 suggested that routine
elastic tissue staining should be performed as a standard
method for assessing pleural involvement in pleura-based
NSCLC owing to false negatives for VPI that occurred in
19% of the group stained with hematoxylin and eosin alone.
In the current study, we divided the tumors into P0, P1, and
P2 subgroups according to the depth of VPI. Using a similarThe Journal of Thoracic and Cclassification, Ohta and colleagues19 reported patients with
P2 showed a significantly poorer survival and shorter dis-
ease-free interval than did patients with P0 and P1. Our pa-
tient cohort demonstrated an actual 5-year survival of 64.3%
in the P0 group. Intergroup comparison failed to demon-
strate significant survival differences (Figure 4). However,
Cox proportional hazards model revealed VPI as an inde-
pendent prognostic factor (P ¼ .0131).
Mizuno and associates14 identified tumors without pleural
invasion as a subgroup with a better outcome in stage IB ad-
enocarcinoma. The 5-year survival of those 76 patients was
almost the same as that of patients with stage IA adenocarci-
noma. On the other hand, the 5-year survival for patients withFIGURE 7. Survival analysis according to the extent of lymphadenectomy. Patients who received a more extensive lymphadenectomy (A, retrieved nodes
>14; B, D2 dissection) also had a better outcome.ardiovascular Surgery c Volume 138, Number 2 431
G
T
S
General Thoracic Surgery Hsu et alstage IB disease with pleural invasion was significantly
poorer than that for patients with stage IB disease without
pleural invasion. These data suggest that visceral involvement
itself is a poor prognostic factor. Nevertheless, a report based
on data from the California Cancer Registry indicated 43.2%
of the stage IB tumors were staged owing to VPI (T2P).3 The
authors claimed that small T2P tumors (3 cm) were a favor-
able prognostic factor with survival similar to that for patients
with stage IA disease. Their data indicate that VPI carries an
increased mortality risk, but this mortality risk is dependent
on the size of the tumor. These findings have also been con-
firmed by Hung and associates,20 demonstrating that small
tumors (<3 cm) of stage IB (T2 N0 M0) NSCLC with VPI
should be treated as T1 disease and not T2 disease owing
to better outcomes. Consistent with the report by Ou and as-
sociates,3 our study showed that tumors with VPI (P2þP1)
were indicative of a significant decline in survival once the tu-
mor size was larger than 3 cm (Figure 6, B). In brief, our data
indicated that impact of VPI on survival is closely related to
the tumor size.
By avoiding stage migration, complete mediastinal lym-
phadenectomy provides the best possibility for accurate
tumor staging and survival benefits.4,21-23 The main purpose
of this study was not to address specifically the extent of
lymphadenectomy. However, we found significant survival
benefits after extensive lymphadenectomy (>14 nodes, Fig-
ure 7, A). Moreover, when 3 or more mediastinal nodal sta-
tions were removed in the lymphadenectomy, patients
survived longer than their counterparts (Figure 7, B). Re-
cently, prospective studies have demonstrated that selective
mediastinal dissection for clinical–surgical stage I NSCLC is
as effective as complete dissection.24,25 This is very impor-
tant in the era of minimally invasive thoracoscopic surgery
on small tumors. If complete mediastinal lymphadenectomy
is unnecessary in early-stage NSCLC, then morbidities re-
FIGURE 8. Survival analysis according to the presence of angiolymphatic
(AL) invasion. Patients who had tumors with positive microscopic angio-
lymphatic invasion had a poorer prognosis.432 The Journal of Thoracic and Cardiovascular Surlated to mediastinal dissection can be avoided and operation
time can be shortened. A recent large series report conducted
in the United States covering a 15-year study period also
demonstrated a tendency toward more extensive lymphade-
nectomy.26 The authors concluded that a higher number of
lymph nodes removed was associated with statistically
significant improvements in overall survival and lung can-
cer–specific survival of patients with stage IA NSCLC
who underwent lobectomy. In the Cox proportional regres-
sion analysis, they found that removal of 11 to 15 lymph
nodes conferred the lowest hazard ratio for mortality. These
findings were consistent with our experiences.
Blood vessel and lymphatic vessel invasions, especially in
small tumors, have been identified as important prognostic
factors.2,14,27 Tsuchiya and associates28 showed that prog-
nosis of patients who have stage IA disease with vessel inva-
sion is similar to that of patients with stage IB NSCLC and
TABLE 2. Multivariate survival analysis by the Cox proportional
hazards model of 272 patients with pT2 N0 M0 stage IB NSCLC
Risk factors
Coefficients
(SE)
Relative
risk (95% CI)
P
value*
Gender .0008
Female (n ¼ 67) 1
Male (n ¼ 195) 0.99 (0.29) 2.69 (1.51–4.79)
Types of resection .4468
Bi-LþL (212) 1
SþW (n ¼ 51) 0.2 (0.27) 1.23 (0.72–2.08)
No. of LN retrieved .0118
>14 (n ¼ 116) 1
14 (n ¼ 146) 0.59 (0.23) 1.80 (1.14–2.84)
Extent of lymphadenectomy .1060
D2 (n ¼ 228) 1
D1 (n ¼ 34) 0.47 (0.29) 1.60 (0.90–2.84)
Cell types .4027
SqCC (n ¼ 96) 1
Adeno-Ca (n ¼ 142) 0.19 (0.23) 1.21 (0.77–1.91)
Others (n ¼ 24) 0.33 (0.42) 0.72 (0.32–1.63)
Differentiation .0024
WD (n ¼ 23) 1
MD (n ¼ 148) 1.33 (0.53) 3.79 (1.33–10.76)
PD (n ¼ 91) 1.78 (0.55) 5.91 (2.01–17.37)
Tumor size .2478
3 cm (n ¼ 101) 1
>3 cm (n ¼ 161) 0.26 (0.23) 1.30 (0.83–2.03)
Pleural involvement .0131
P0 (n ¼ 91) 1
P1þP2 (n ¼ 171) 0.56 (0.23) 1.75 (1.12–2.72)
Angiolymphatic invasion .0500
No (n ¼ 237) 1
Yes (n ¼ 25) 0.55 (0.28) 1.73 (1.00–2.98)
NSCLC, Non–small cell lung cancer; SE, standard error; CI, confidence interval;
Bi-LþL, bilobectomy and lobectomy; SþW, segmentectomy and wedge resection;
LN, lymph nodes; D2, with mediastinal lymphadenectomy; D1, without mediastinal
lymphadenectomy; SqCC, squamous cell carcinoma; Adeno-Ca, adenocarcinoma;
WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated;
P0, no pleural invasion; P1þP2, contiguous subpleural and direct pleural invasion.
*P value by Wald statistic.gery c August 2009
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motherapy to improve long-term survival. Nearly 10% of
our patients had a pathologically proven tumor island within
the lumen of a small vessel or lymphatic channel of the tu-
mor. The clinical significance was reflected by the overall
survivals, which were as low as 29.6% at 5 years. Fourteen
(5.1%) patients with microscopic positive cut margins did
not show decreased survival (P ¼ .3548), which may be
due to small patient numbers or a good response to postop-
erative local radiotherapy.
Taken together, the above results demonstrated that the
accuracy of the T category in predicting prognosis according
to the current TNM staging system is limited by its focus on
the size and location of the tumors regardless of the tumor’s
biomolecular behaviors. Consistent with the report of Jones
and colleagues,29 we found factors causing 5-year survivals
of less than 60% included a cell type of pure adenocarci-
noma, a larger tumor size (>3 cm), existence of direct and
contiguous subpleural invasion, existence of angiolym-
phatic invasion, a limited pulmonary resection, and a less
extensive mediastinal lymphadenectomy. Among these,
the pathologic findings in particular may indicate the need
to up-stage the tumor as stage IIA. In another way, the cur-
rent TNM staging system may need to be annotated using
stage IB(þ) to indicate a more promising (favorable) out-
come or stage IB() to indicate a more negative (unfavor-
able) outcome for patients with the same stage IB disease.
In summary, stage IB NSCLC comprises a heterogeneous
group of node-negative tumors with different prognoses.
The current staging system includes tumors either with
a prognosis similar to that of stage IA tumors or with a prog-
nosis the same as that of stage IIA tumors. This discrepancy
may cause confusion in decisions about postresectional ad-
juvant therapy. Modification of the current TNM staging cri-
teria by up-staging or annotation and taking consideration of
the surgical–pathologic factors that cause 5-year survivals of
less than 60% may be needed to make the forthcoming ver-
sion of UICC/AJCC TNM staging manual one that more
accurately reflects recent findings.
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